Dr. John Leonard on Treatment Options for Relapsed Follicular Lymphoma

Name: Dr. John Leonard on Treatment Options for Relapsed Follicular Lymphoma
Uploaded: 2016-03-20T08:17:00.000Z
Description: John Leonard, MD, medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses follicular lymphoma treatment considerations. Treatment options include rituximab and bendamustine, which have been around for sometime, as well as newer agents like obinutuzumab, says Leonard.

March 20, 2016

John Leonard, MD

Video

Conference|PER® Congress on Hematologic Malignancies (Winter Hematology®)

John Leonard, MD, medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses follicular lymphoma treatment considerations. Treatment options include rituximab and bendamustine, which have been around for sometime, as well as newer agents like obinutuzumab, says Leonard.

John Leonard, MD, medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses treatment considerations for patients with follicular lymphoma.

Current treatment options include rituximab and bendamustine, which have been around for sometime, as well as newer agents like obinutuzumab, says Leonard. There is also data that shows that idelalisib, a P13-kinase inhibitor, can work in rituximab-refractory patients, says Leonard. R-CHOP is another options as well as radioimmunotherapy and stem-cell transplant.

Several clinical are also investigating new agents in relapsed follicular lymphoma. These include the AUGMENT study, a double-blind randomized, parallel group study that is evaluating the efficacy and safety of lenalidomide in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

<<<